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If you would like to contribute to Participate or for further information please contact
Jenny Oskiera j.oskiera@warwick.ac.uk  
A New Era has Begun
With the dawn of a new era for the NHS beginning in April, primary care research faces  
a new set of questions and challenges.  Primary Care Trusts (PCTs) have been replaced by 
Clinical Commissioning Groups (CCGs) and the local area teams of NHS England.  The need 
for evidence generated by primary care research to inform commissioning, clinical practice and 
the development of the NHS has never been greater. 
 Alongside this, the NIHR research networks are undergoing transition towards becoming,  
in 2014, a much smaller number of integrated, region-wide networks.  Although, within this 
environment, there is a risk of primary care research slipping down the priorities list, we have 
not seen any evidence of this happening 
locally.  Patients continue to rely on 
primary care for first-contact care, 
preventive care, management of long 
term conditions, end of life care, and 
more.  In a cash-strapped NHS facing 
the consequences of the socio-
demographic and economic challenges 
that are increasing the need for 
healthcare, clinically effective, cost-
effective approaches to primary care 
are essential.  In the wake of the Francis 
Inquiry Report, the need for greater 
focus on safer and more compassionate 
care has also been highlighted.   
2012/13 proved to be a record year 
for primary care recruitment in West 
Midlands South (WM-S), with 8,708 
patients recruited to date, just under 
73% increase on the previous year.  
Over 100 practices participated in 
research, and a total of 60 primary  
care studies recruited within the area.
In this edition of Participate, we can 
see how primary care research is 
thriving locally.  The research incentive 
scheme is being taken up by an 
increasing number of GP practices 
across WM-S as highlighted on page 6; 
there have been successful research 
network meetings held across the 
region, and in Worcestershire a new research partnership has been launched – the 
Worcestershire Health Research Collaboration – both detailed on page 7.
We also feature information on ongoing and new studies: from testing an online self-
assessment tool for patients with mental health problems (page 3); to investigating the genetic 
factors associated with thinness and determining whether a simple postal intervention from a 
GP will reduce asthma exacerbations and unscheduled medical contacts for school age children 
on their return to school in September (page 4). In addition, the article on page 10 will be of 
interest to those who would like to contribute to the feasibility of a research programme being 
developed tackling child bullying in primary care.
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Current PCRN Studies
For more information please contact Dr Saravanan  
p.saravanan@warwick.ac.uk or his PRiDE study team at 
pride-study@warwick.ac.uk telephone 02476 153592,  
or Facebook page, PRiDE Study, or follow us on Twitter  
@PRiDEStudy for the latest updates.
PRiDE Study Update: 
Micronutrients in 
Pregnancy as a Risk Factor 
for Gestational Diabetes
 The PRiDE study team are proud and grateful to all those 
who are helping to make recruitment a success. With around 
150 recruits in both sites (Nuneaton and Warwick), it is 
evident that there is growing interest and enthusiasm amongst 
both the healthcare providers and participants alike. With the 
first PRiDE baby expected in April, we hope to carry on the 
study with follow up of the next generation for evidence of 
early metabolic changes.
The timing of visits to routine hospital appointments and 
the observational nature of the study is attracting many willing 
mothers in their first trimester of pregnancy to help with this 
research on vitamin insufficiency as a potential risk factor for 
gestational diabetes (GDM).  
This multicentre Medical Research Council-funded study 
aims to recruit approximately 4,500 women from different 
ethnic groups over three to four years, making it one of the 
largest trials on GDM in the UK. Women with traditional GDM 
risk factors will be enrolled in the first trimester of pregnancy 
and followed up to six weeks post-delivery. Primarily 
investigating micronutrient imbalances in GDM, PRiDE also 
hopes to provide insight into many unknown aspects of 
GDM’S causation and outcomes in a multi-ethnic population.
The research team has been strengthened by two research 
fellows – Dr Sukumar and Dr Venkataraman (senior trainees 
in Diabetes and Endocrinology) as well as research nurses 
Polymyalgia 
Rheumatica Study
Polymyalgia Rheumatica (PMR) is the 
commonest inflammatory rheumatological 
condition in older adults, but has received little 
research attention, especially in the primary care 
setting - where most patients are diagnosed and 
managed. The PMR Study is a cohort study of 
newly diagnosed PMR patients in primary care. It is funded by 
Arthritis Research UK and is being run by Professor Christian 
Mallen, an academic GP based at Keele University. The aim of 
the study is to describe the epidemiology of PMR in the 
community over two years. Patients are recruited within the 
consultation, and referred to the research centre at Keele by 
fax. The study is currently recruiting in practices throughout 
the Central England PCRN and is beginning in other English 
regions. So far, 83 people have been referred to the study.
and midwives at both sites.  Scientists based at Warwick 
Medical School are working closely with the PRiDE team to 
study molecular, genetic and metabolic changes that 
characterise GDM in different ethnic groups. This may help 
early identification of GDM and its prevention.
 Currently, participant identification is being carried out by 
community midwives during booking visits at GP surgeries or 
children’s centres. Recruitment is then undertaken in hospital 
at the dating scan/booking bloods. However, interested GP 
practices are welcome to get involved in both identification 
and recruitment.
 The PRiDE team invites community midwives, practice 
nurses, GPs and anyone else involved in the care of pregnant 
mothers in the first trimester to participate in this unique study 
to help mothers at risk of GDM in our region. With your help 
we hope to increase our recruitment to meet our targets.
For more information, or if you would like to take part, 






Helicobacter eradication to prevent ulcer bleeding in 
aspirin users: a large simple randomised controlled trial
Principal investigator Birmingham region: Prof Richard Hobbs.
Locations: ~400 GP practices in Birmingham and Black Country, 
Worcestershire, Coventry and Warwickshire, Shropshire, Staffordshire, 
Herefordshire, Stoke, Telford and Wrekin, Wolverhampton, Sussex 
and Surrey, Nottingham, Durham, Southampton and Oxford.
Enrolment period: 2012 – June 2014.
Participants: Men and women aged 60+, infected with H. pylori, 
who are using aspirin <326mg daily.
Other information: This trial has been preceded by a successful pilot 
study, funded by the Medical Research Council. Practices will be 
reimbursed for their time.
 Use of aspirin for cardiovascular prophylaxis is widespread and 
increasing.  The main hazard is ulcer bleeding.  This is usually 
associated with H. pylori infection.  It is important to determine 
whether this can be reduced or prevented by H. pylori eradication. 
The trial hypothesis is that aspirin does not itself cause peptic  
ulcers, but that it promotes bleeding of ulcers caused by H. pylori. 
Given the scale of aspirin use, its continuing increase and its 
contribution to ulcer bleeding, how to deal with this problem is 
arguably the most important question with regard to current 
iatrogenic medicine.
 Intervention and clinic: suitable patients will be identified by their 
surgery, using an automated search, and then asked to attend an 
appointment with a university research nurse or practice nurse 
(relevant training will be provided) to consent to the trial and take a 
H. pylori breath test. Those with a positive result will be randomised 
to receive a one week course of either eradication treatment or 
placebo, supplied by the trial centre. No follow-up visits for the patients 
are required, but any hospital admissions for ulcer bleeding will be 
recorded over a period of two to three years by the trial centre.
For further information please contact Dr. Ann Adams 
a.e.adams@warwick.ac.uk 
Self-management  
of Mental Health  
Problems and  
Saving GPs’ Time
Calling all GPs – would you like to save time in mental health 
consultations? Would you like patients to arrive with a detailed, 
self-generated risk history? Would you like patients to be better  
able to make sense of and to articulate their risk and safety 
concerns? Would you like to avoid asking patients difficult risk 
questions, about suicide for example? Researchers at the 
Universities of Warwick and Aston can help. We are seeking  
GPs and patients to take part in a study testing out myGRiST  
– an online self-assessment tool which complements clinical  
versions of GRiST www.egrist.org.
Further information: If you would like to find out more,  
please contact the trial manager for your region, Rachel Iles  
(r.iles@bham.ac.uk 0121 414 2691).
We are looking for families with children  
aged seven to 11 who are overweight
The project is funded by the NIHR HTA programme.
Childhood obesity is a concern with a quarter 
of school-aged children in the UK having excess 
weight which may be detrimental to their 
health. Warwick Medical School, in conjunction 
with NHS Coventry, NHS Warwickshire and NHS 
Wolverhampton City PCT are testing a new 
family-based intervention called ‘Families for 
Health’ (FFH), designed to support families 
with children who are overweight or obese.
All families that participate will receive  
support and will be randomly allocated to 
either FFH or ‘usual care’. FFH is a 10 week 
group-based programme which aims to support 
families in adopting healthy lifestyle 
behaviours in a friendly, fun and supportive 
community environment.  Usual care varies  
by location, but may include one-to-one  
support or other group-based programmes.
“We thoroughly enjoyed the Families for 
Health programme, it was a lot of fun and  
we found we radically changed our portion 
sizes as a result” MRS B, COVENTRY 
For further information or to refer  
a family please contact the Families  
for Health team at FFH@warwick.ac.uk  
or telephone 02476 151 864.
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New PCRN Studies
For many people, losing weight is a 
constant battle. High calorie food is 
available 24/7 and as a society we are 
less physically active, factors that are 
contributing to the rising tide of being 
overweight and obesity. However,  
some people manage to eat what  
they like and don’t worry about their 
weight. What’s their secret? Family, twin 
and adoption studies have shown that 
thinness is highly heritable in families. 
The aim of STILTS2 is to recruit a 
cohort of thin people, with the help  
of the PCRNs, for a comprehensive 
genetic study which would be the first 
of its kind in the world.
The Study Into Lean and Thin Subjects 
(STILTS2), funded by the European 
Research Council, aims to recruit 1,500 
thin people (BMI<18kg/m2), who are 
well, do not have eating disorders or 
exercise excessively. GP practices are 
asked to identify eligible participants 
through a database search and send 
invitation letters. Interested participants 
reply to Professor Farooqi’s team in 
Cambridge, who have identified many 
genes that contribute to obesity  
(www.goos.org.uk). The research team 
send participants a consent form,  
Preventing and Lessening 
Exacerbations of Asthma  
in School age Children 
Associated with a New Term
The trial is being managed  
by The Sheffield Clinical Trials 
Research Unit (University  
of Sheffield) in collaboration 
with the Clinical Practice 
Research Datalink (CPRD).
The PLEASANT study  
is a cluster randomised 
controlled trial looking  
for 140 general practices to be involved across England  
and Wales. The purpose of this research is to see whether  
a simple postal intervention from the GP will help to  
reduce exacerbations of asthma and unscheduled NHS 
If you wish to take part but your practice is not yet registered on the CPRD, please follow the link below to register  
your practice: www.crncc.nihr.ac.uk/cprd-eoi and send your expression of interest to Dr Michelle Horspool, trial manager  
m.horspool@sheffield.ac.uk.  The closing date for GP recruitment is mid June 2013 with delivery of the intervention by  
29th July 2013. For further information please visit: http://www.shef.ac.uk/scharr/sections/dts/ctru/pleasant
Recruitment began in July 2012 and thanks to support from the many PCRNs and CLRNs, almost 600 participants  
have enrolled. STILTS2 is open for recruitment, so please contact Aman Johal, PCRN WM-S research facilitator,  
at amanpreet.johal@warwick.ac.uk or telephone 02476 574127 for further information.
contacts in school age children associated with the return  
to school in September.
Practices will need to be signed up to the CPRD in order 
to take part in this study and will need to be using the Vision 
practice database system.
Why Can Some 
People Eat  
What They Like 
and Never Gain 
Weight? UKCRN 12511
a basic questionnaire and a saliva kit  
for DNA collection. Once recruitment 
is complete, the DNA will be analysed 
using state of the art genomics technology 
that investigates millions of variants in all 
the genes in the human genome. Results 
from STILTS2 will be compared to 
7,000 normal weight controls and 2,000 
people with severe obesity. This powerful 
design will provide unique information 
about the genetics of thinness and inform 
the prevention and treatment of obesity.
Image courtesy of mikumistock at FreeDigitalPhotos.net
Image courtesy of Master Isolated Images at FreeDigitalPhotos.net
Image courtesy of Grant Cochrane at FreeDigitalPhotos.net
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UK Clinical Ethics Network
We are delighted to invite you to the  
13th Annual Conference of the  
UK Clinical Ethics Network 
Ethics of Healthcare in a Multicultural Society 
19th June 2013 
 
Aston University,  
Lakeside Conference Centre, Birmingham 
This conference will be of interest to clinicians & non-clinicians working in the health 
services, anyone involved with clinical ethics support or with an interest in the 
ethical dimension of health care. 
 
Speakers include 
Professor Gurch Randhawa University of Bedfordshire  
Professor Jean McHale  Birmingham Law School 
Professor Bill Fulford  University of Warwick 
Professor Stephen Pattison University of Birmingham 
Professor David Salla  University of Wolverhampton  
 
Debate 
“Is culture based healthcare unaffordable in the NHS?”   




Online Registration:  https://b-com.mci-group.com/Registration/ 
For further details please visit our website: www.ukcen.net 
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If your practice is interested in becoming a RIS practice or 
would like further information please contact Sue Elwell on 
s.elwell@warwick.ac.uk or 02476 575854.
If you have any further queries regarding the above,  
or if you are approached by any other organisations 
requesting your participation in research, please contact 
Sue Elwell, research manager, on s.elwell@warwick.ac.uk  
or by phone 02476 575 854.
Primary Care  
Research Governance  
post 1st April 2013
Introduction
In light of recent changes within the NHS, the process for 
granting NHS Permission for primary care research is changing.   
PCRN WM-S is providing reassurance to GP teams taking 
part in research within our area that the research governance 
arrangements of PCRN-supported research studies will 
continue to be managed locally in accordance with the 
discussion paper issued by the Department of Health
‘Determining arrangements for supporting 
research in primary and community care’.
Location of RIS practices:
Coventry 9 practices 
Herefordshire 5 practices
North Warwickshire 6 practices
South Warwickshire 13 practices
North Worcestershire 6 practices
South Worcestershire 10 practices
RIS 2012-13
In 2012-13 54 practices participated in our RIS 2012-13 at 
Level 1, Level 2 or as Host Practices. Recruitment this year 
has been outstanding, exceeding all targets and having grown 
by almost two-thirds compared to 2011-12.  We would like  
to offer our thanks, and hearty congratulations to all the 
practice teams who took part.
During the year we held a series of local area research network 
meetings, with a chance for people from different practices to 
meet each other, hear about current research, swap ideas and 
enjoy a networking opportunity. These were well attended and 
fostered an awareness of the wider ‘family’ of staff and practices 
involved with PCRN WM-S in primary care research.
Numbers Recruited 2012-13 to date
PCRN West Midlands 
(South) Research Incentive 
Scheme (RIS) 2013-14
We are pleased to announce that the local RIS, now entering 
its third year, is continuing with 56 practices, including  
10 new to the scheme, planning to participate.
West Midlands South Sub-Team Areas: 
Herefordshire, Worcestershire (North and South),  
Coventry, Warwickshire (North and South)
Current and Future Arrangements
All studies that the PCRN offers to primary care teams are 
on the National Institute for Health Research (NIHR) 
Portfolio. The Portfolio comprises of studies which are 
well-planned, peer reviewed, high quality, and have a clear 
relevance to the NHS.  In addition each study has approval 
from a Research Ethics Committee (REC) and until now has 
had local approval from a PCT.  
NHS Permissions that have already been issued by a PCT 
remain valid; there is no requirement for further review or 
approval of these studies.   However, from April 1st, 
agreement by an Independent Contractor to participate in a 
research study will constitute NHS Permission.
These changes should not significantly alter the experience 
for researchers and GP practices participating in Portfolio 
research; therefore please do continue to conduct research in 
accordance with current best practice and regulatory 
guidance.  The West Midlands (South) CLRN will continue to 
assess and quality assure each study against a range of 
research governance criteria, including checks on Financial 
Management, Sponsorship, Study Documentation, and other 
applicable laws, regulations and guidelines. In addition to the 
research governance assurance provided by West Midlands 
(South) CLRN, the study will also be reviewed by the local 
PCRN study group; a multidisciplinary group which includes 
GPs and other experienced research staff.  
West Midlands (South) CLRN and PCRN will continue to 
work closely to ensure a high quality local research agenda, 
and as further guidance becomes available, we will continue 
to keep all research-active primary care teams updated. 
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PCRN Research and Governance
The PCRN WM-S team successfully 
launched its first series of local research 
network meetings in December and January. 
In total five meetings were held at various 
local venues across the region. As part  
of participation in our RIS 2012-13 GP 
practices and local Clinical Commissioning 
Group (CCG) representatives were  
invited to attend the events, organised  
by our local sub-teams.  
The meetings offered research 
participants an opportunity to meet and 
connect with others in their area, thus 
building a local research network to 
encourage sharing of research experience.  
For further information on this year’s  
RIS and our research studies please 
contact Sue Elwell, research manager,  
on 02476 575854.
For further information on NIHR Portfolio 
studies in Worcestershire please contact 
Aman Johal, PCRN WM-S research 
facilitator, at amanpreet.johal@warwick.ac.uk 
or 02476 574127. For further details about 
WHRC please contact Professor V Wilkie, 
Academic and Learning Lead for South 
Worcester CCG and Professor of  
Primary Care, Worcester University at  
veronicawilkie456@btinternet.com
Launching the Worcestershire Health Research  
Collaboration (WHRC)
and Patient and Public Involvement groups 
were also present.
WHRC has been established to promote 
and support health research in 
Worcestershire through collaboration 
between NHS organisations, NIHR clinical 
research networks, the University of 
Worcester and other interested research 
partners. In addition to encouraging 
participation in NIHR Portfolio research,  
They also acted as a forum to disseminate 
research findings and discuss the feasibility 
of ideas for locally-led studies.
Topics discussed included a review of the 
RIS and the PCRN strategy, progress and 
feedback on local studies including recruitment 
figures, results of completed studies that had 
impacted clinical practice and a highlight of 
new research trials including a presentation 
from one of the PCRN WM-S research 
fellows on a proposal for a research project.
The meetings were well-attended with 
participants being engaged, provoking lively 
and interesting discussions. Overall feedback 
was very positive with a strong sense of 
It’s Good to Network
goodwill towards research participation and 
a palpable shift in the integration of research 
into everyday clinical practice for those 
involved. The RIS was heralded as a success 
in enabling and retaining GP practices to 
undertake research, reflected in comments 
such as:
“We have managed to recruit 
more patients and get more 
doctors involved.”
and the call for it continues. The events also 
provided a forum for opening up dialogue 
between the PCRN and local CCG members. 
Importantly, this was an opportunity to show 
gratitude and appreciation of GP practices’ 
contributions to primary care research.
For the future, the annual local research 
network meetings will continue to occur as 
an important part of practices’ participation 
in PCRN Portfolio research. As one 
attendee said:
“We don’t seem to meet like this 
very often, it’s good to do so.”
it aims to stimulate new research studies  
as well as fostering teaching opportunities 
for NHS professionals at the University.
Past, present and future NIHR Portfolio 
research occurring in Worcestershire was 
showcased alongside the local PCRN 
support available. Current studies highlighted 
included PreFit (Prevention of Fall Injury Trial) 
and the 3C (Cough Complication Cohort) 
study and new research such as HEAT 
(Helicobacter Eradication Aspirin Trial) and 
DAPA (Dementia and Physical Activity) trial 
were also promoted.
The local PCRN WM-S team played a  
key role in the successful launch of the 
WHRC at an open meeting on March  
13th at the University of Worcester.  
Academics, clinicians, research & 
development managers attended from 
across Worcestershire NHS hospital and 
community trusts, Clinical Commissioning 
Groups (CCGs) and the University. 
Representatives from medical charities  
Page 8
PCRN Study Update
For further information, please contact the ISICA Project Manager 
Stefanie Pohlmann, tel: 0203 1375 828, fax: 0207 4867 231 email: 
spohlmann@la-ser.com, email the study team at isica@la-ser.com  
or click on this link: http://www.crncc.nihr.ac.uk/about_us/pcrn/pc_
news/pc_news_archive/ISICA_sucess
International Study of  
Incident Cancer (ISICA)  
– Breast Cancer and Diabetes
The ISICA study, as requested by the European Medicine Agency 
(EMA), has been investigating the association between the 
occurrence of breast cancer and diabetes and diabetes treatment.
1,296 control patients were recruited in the UK within just 10 
months of the study opening, smashing the UK’s target of 1,000.  
In England alone 1,140 patients were recruited from a total of 71  
general practices – all via the Primary Care Research Network. The 
study met its global target with the UK coming a close second to France 
and ahead of Canada. But in terms of drop out rates, the UK was head 
and shoulders above the other two countries. Says Stefanie Pohlmann:
“UK patients were very committed to the study once 
they had agreed to take part. This was seen as a very 
positive aspect of the UK’s participation.”
The past two years have been very successful thanks 
to your hard work and commitment. A big thanks to 
everyone involved - you made ISICA a success!
And the extraordinary effort of the Network has been duly noted:
“The study would have been virtually impossible to do 
without the support of both parts of the Network”,
“I’ve worked with PCRN before, so I knew what to expect, 
but NCRN was equally effective. They provided a good 
range of hospitals. They are definitely well connected and 
the communication was excellent. Without Network support 
we would have had to take an entirely different approach.”
If you would like any further information, 
please contact Deborah A Popoola, 
PRIMIT trial coordinator on  
0121 414 4839 d.a.popoola@bham.ac.uk
A Primary Care Trial of a Website-
Based Infection Control Intervention 
to Modify Influenza-like Illness and 
Respiratory Infection Transmission
This study has now completed its final stage of 
recruitment. Over 300 practices were involved 
nationwide in this study and the PRIMIT study 
team would like to take this opportunity to 
thank all the practices involved.
Locally PCRN West Midlands South 
recruited 1,004 patients into this study over 
the three month period that the study was 
recruiting.
The final stage for the study comprises a 
notes review of the participating patients, and 
we will be contacting all practices involved to 

































New Study for Cancer  
Patients with Venous  
Thromboembolism:
select-d: Anticoagulation Therapy in SELECTeD Cancer Patients at Risk of Recurrence of Venous Thromboembolism
The secondary objectives include:
•  To record the number of times parents make urgent contact 
with healthcare professionals
•  To investigate the acceptability of CHAT/ HMP from the 
perspective of parents of infants with complex congenital  
heart disease
•  To gain estimates or trends of effectiveness of CHAT/ HMP 
(Group A) compared with CHAT alone (Group B) and  
with usual discharge care (Group C) in alleviating anxiety  
and depression in parents, increasing confidence, and in 
reducing hospitalisation and/or mortality among the infants
•  To explore whether parental demographics and psychosocial 
functioning have an impact on the transition from hospital to 
home and whether there is any comparison or connection to 
individual groups of parents (A, B and C)
The research is supported by Heart Research UK, who are funding 
the equipment, and the Research Nurse and Little Hearts Matter, 
who are involved in developing the CHAT and standard discharge 
information leaflets. The project is taking place at the Birmingham 
Children’s Hospital.
 The project will test the feasibility of using a Congenital Heart 
Assessment Tool (CHAT) as part of a Home Monitoring 
Programme (HMP) for infants with single ventricle heart conditions 
(infants born with only one side of the heart pump, an extremely 
serious non-correctable condition which is treated through a series 
of complex heart operations) or those with systemic shunt-
dependent heart conditions.
 The HMP includes daily measurements by parents of their 
infant’s oxygen levels and weight, whilst discharged home between 
the first and second surgery. The CHAT uses a traffic light system  
to give an early indication of deterioration of the infant’s condition, 
informing parents and medical teams promptly about problems to 
enable early treatment. 
The principle purpose of the feasibility study is to inform the 
development of a future research application for a large multicentre 
randomised controlled trial, by assessing:
•  Rates of recruitment to the study and recruitment strategies
•  Follow up, and questionnaire completion rates
•  Proportion of eligible parents entering the study and  
reasons for non-participation 
For further information please contact Kerry Gaskin  Tel: 02476 795 854 or email hsx562@coventry.ac.uk
For further information contact select-d@warwick.ac.uk or call Jenny Phillips,  
trial coordinator 02476 573315.
select-d is a prospective, randomised,  
open label, multicentre pilot study 
comparing dalteparin versus rivoraxaban 
with a second placebo-controlled 
randomisation comparing the duration of 
anticoagulation therapy (six months versus 
12 months treatment) in patients with  
DVT (deep vein thrombosis) who are 
Residual Vein Thrombosis [RVT] positive 
(+ve). All patients presenting with PE 
(pulmonary embolism) will be invited to 
participate in the second randomisation.
A Feasibility Study of Parental Home 
Monitoring and Assessment of Infants 
with Complex Congenital Heart Disease
Recruitment period: May 2013 – May 2015
Eligible patients: Aged > 18 with active 
cancer and a primary presentation of an 
objectively confirmed VTE – symptomatic 
lower extremity proximal DVT or 
symptomatic or incidental PE          
Update: select-d has received ethics  
and MHRA approval and aims to start 
recruitment in May 2013. Many eligible 
patients will present to their GP with 
suspected VTE; please refer as usual  
practice and inform patients of the 
possibility of the select-d trial. All centres 
throughout the West Midlands are keen  
to participate; Birmingham and Warwick 
patients with cancer and VTE have 
opportunity to enter another trial for the 
treatment of VTE called ‘ALICAT’.
Treatments: 
Dalteparin (Fragmin®, Pfizer), a low molecular 
weight heparin, the only licensed anticoagulant 
in the UK for the extended treatment and 
prevention of recurrence of VTE (venous 
thromboembolism) in cancer patients.
Rivaroxaban (Xarelto®, Bayer), an oral direct 
Factor Xa inhibitor, licensed for the 
treatment of DVT and the prevention of 
recurrence of DVT and PE in adult patients.
Chief Investigator: Professor Annie Young
Sponsor: University of Warwick
Funder: Educational grant from Bayer plc 
(Investigator Initiated Study) 
Sites: 50+ sites
Recruitment target: 530 patients
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Local Research
For further information, please contact  
Professor Dieter Wolke d.wolke@warwick.ac.uk or  
Professor Jeremy Dale jeremy.dale@warwick.ac.uk
Further information on the projects can be found 
at http://wmshiec.org/Our-Projects/
West Midlands South 
Health Innovation & 
Education Cluster - 
Innovating in the Local 
Healthcare Economy *
 The West Midlands South Health Innovation & 
Education Cluster (WMS HIEC) was established  
in 2010 as a partnership of twelve NHS, charity, 
university and private sector organisations.   
It was one of 17 HIECs nationally, with a brief  
to improve the skills and experience of NHS  
staff and to develop and spread innovation in 
healthcare.  Researchers in a team led by  
Coventry University have been evaluating the 
impact of the WMS HIEC.
WMS HIEC has operated across an area  
seen by participants as having a ‘natural geography’ 
and having a good balance of urban and rural, 
affluent and socially deprived areas with a spread 
of healthcare providers.  Since it was formed  
in 2010, it has funded 16 innovation projects 
covering a wide range of conditions from  
diabetes, dementia, cardiac care, COPD (chronic 
obstructive pulmonary disease), stroke to sexual 
and mental health.  
During a period of considerable uncertainty, 
brought about by the strategic and organisational 
changes in the NHS during its period of operation, 
projects funded by WMS HIEC have developed new 
clinical pathways, improved patient self-management, 
trained healthcare staff, improved access to 
specialist facilities, and developed innovations to 
help improve awareness, change attitudes and 
lifestyle behaviours, and improve public health.  
WMS HIEC has added value to its core funding 
role because of its light touch but ‘hands on’ 
approach, its emphasis on partnership working, its 
positive relationships with projects and its flexible 
approach to funding.  Its lean operation has been a 
strength, helping it to get closer to the work of the 
projects and ensuring that partners themselves 
‘owned’ the projects.  The local focus has led to 
benefits in terms of gaining acceptability in host 
organisations and is helping to spread project 
benefits through local and professional networks.
WMS HIEC leaves a legacy of genuinely 
collaborative working, with perhaps a greater 
mutual respect between academic, clinical and 
private sector partners.  It has offered a glimpse  
of what can be achieved with cross sector 
collaboration. 
Tackling Child Bullying  
in Primary Care: 
adult psychiatric outcomes of  
bullying and being bullied by peers  
in childhood and adolescence
Bullying refers to intentional repeated harm by individuals or groups, 
either directly (verbal or physical) or indirectly (spreading rumours).  
It may occur in peer settings (e.g. school), but has proliferated 
through electronic media usage (cyber bullying) with children possibly 
exposed to bullying 24 hours a day. Its prevalence is approximately 
20-30%, with 10-14% of children experiencing chronic bullying over 
years. Many children suffer in silence; 40% do not tell their parents, 
less than half speak to their teacher.  For further information please 
follow: www.warwick.ac.uk/gpbullyingresearch/resultssummary 
Being bullied has serious implications: physical and mental health 
problems (from headaches to depression to psychosis), self-harm 
and suicidal behaviour and school absence. It impacts on adult mental 
and general health, reducing the ability to maintain work, financial and 
social stability. A recent paper in JAMA Psychiatry found childhood 
bullying predicted general anxiety disorders, panic disorder, 
agoraphobia, depression, and suicidal acts in adulthood. 
We are developing a research programme that aims to establish  
the prevalence of childhood bullying presenting to general practice,  
to design a training programme for primary care clinicians, and test  
the effectiveness of a widely accessible intervention.  
We would like to hear from GPs or practices that would be 
interested in contributing to the planned feasibility work.
*Members of the evaluation team were Katrina Ritters, 
Professor Howard Davis, Dr Carol Grant-Pearce (Coventry 
University), Professor Jeremy Dale (Warwick Medical School) 
and Dr Peter Watt (Birmingham University).
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West Midlands (South) CLRN Update
If you would like further information about the patient and public involvement work at 
West Midlands (South) CLRN, please contact Mohammed Shaikh, Patient and Public 
Involvement Officer on 07825 341 182 or email mohammed.shaikh@uhcw.nhs.uk
For more information,  
or to register your interest 
please contact Karen Johnson at 
wmsouthclrn.admin@uhcw.nhs.uk 
or call 02476 965 143.
International 
Clinical  
Trials Day  
Monday 20th May 2013
West Midlands (South) CLRN  
is supporting International  
Clinical Trials day on Monday  
20th May 2013 by organising  
a display stand at University  
Hospitals Coventry and  
Warwickshire NHS Trust,  
Walsgrave, Coventry, main reception 
10.00a.m – 2.00p.m.  This will  
include a video on the experience  
of patients and members of the  




& Planning  
for the Future
We are delighted to announce the 
launch of our fifth annual event to 
be held on Monday 1st July from 
9.00 a.m. until 4.30 pm. at the 
Stratford Manor Hotel, Stratford 
upon Avon, CV37 0PY. Further 
details will be available soon, so 
please mark this date in your diary. 
Registration is free and lunch and 
refreshments will be provided.
West Midlands (South) CLRN  
Patient and Public Advisory Group
The West Midlands (South) CLRN Patient and Public Advisory Group is gaining momentum 
and increasing membership.  The group now has eight members and is looking for more to 
join from across Coventry, Warwickshire, Herefordshire and Worcestershire.  This group 
meets monthly at the University of Warwick, 4.30p.m. – 6.00p.m.  Travel expenses are paid 
and refreshments are provided. Dates for 2013 are as follows:
• Tue 7th May 2013 • Tue 3rd September 2013
• Tue 4th June 2013 • Tue 8th October 2013
• Tue 2nd July 2013 • Tue 5th November 2013
• Tue 6th August 2013 • Tue 3rd December 2013
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West Midlands (South) CLRN Courses
Course Title Date Time Location
Informed Consent 3rd May 2013 13.00 -15.30 University Hospital Coventry
Introduction to  
Good Clinical Practice
9th May 2013 08.45 -15.45 University Hospital Coventry
Introduction to Patient &  
Public Involvement in Research
14th May 2013 10.00 -12.45 Hereford County Hospital
Introduction to Research 
Management & Governance
16th May 2013 9:00 – 12:00 University Hospital Coventry
GCP Refresher 5th June 2013 9:15 – 12:00 Warwick Hospital
Paediatric Consent 6th June 2013 9.30 – 11.30 University Hospital Coventry
Introduction to  
Good Clinical Practice
14th June 2013 08.45 -15.45 Warwick University Clinical Trials Unit
Introduction to  
Good Clinical Practice
12th July 2013 08.45 -15.45 Worcester Royal Hospital
Site File Auditing 17th July 2013 13.00 - 16.00 University Hospital Coventry
Academy for Research  
Active Professionals
Course Schedule: May – July 2013. 
New course dates are added on a regular basis.  
For further information or to be added to the circulation list,  
please email wmsouthclrn.academy@uhcw.nhs.uk
For more information about PCRN WM-S please contact:
Primary Care Research Network Central England  
(West Midlands South)




Tel: 02476 575767 or 02476 575919
Fax: 02476 528375
Website: www.warwick.ac.uk/go/PCRN
For further information about this newsletter  
please contact Jenny Oskiera j.oskiera@warwick.ac.uk  
or Tara Al-Salihi t.al-salihi@warwick.ac.uk
